肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定

2019-11-21 Allan MedSci原创

日本厚生劳动省弥漫性大B细胞淋巴瘤Polatuzumabvedotin
关注

Chugai制药株式会社近日宣布，正在开发中的抗CD79b抗体-药物偶联物Polatuzumab vedotin获得了厚生劳动省（MHLW）的孤儿药认定，用于治疗弥漫性大B细胞淋巴瘤（DLBCL）患者。

Chugai制药株式会社近日宣布，正在开发中的抗CD79b抗体-药物偶联物Polatuzumab vedotin获得了厚生劳动省（MHLW）的孤儿药认定，用于治疗弥漫性大B细胞淋巴瘤（DLBCL）患者。该项决定是基于Ib / II期临床研究（GO29044研究和GO29365研究）的最新结果，Polatuzumab vedotin分别被用于治疗初治DLBCL和复发难治DLBCL患者。

Chugai执行副总裁Yasushi Ito博士说：“尽管初治DLBCL患者的标准疗法是利妥昔单抗和化学疗法的组合，但这种疾病在约40％的患者中复发。因此急需治疗此类复发性DLBCL。我们将继续药物上市做准备，以便尽快将Polatuzumab vedotin作为新的治疗选择提供给患者”。


原始出处：

http://www.firstwordpharma.com/node/1682265#axzz65rp59sut

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1912252, encodeId=604219122527a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Sep 21 16:01:00 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702599, encodeId=0e991e02599ca, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Tue Jun 02 18:01:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634479, encodeId=ccd016344e94d, content=<a href='/topic/show?id=03454543528' target=_blank style='color:#2F92EE;'>#孤儿药认定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45435, encryptionId=03454543528, topicName=孤儿药认定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f66f22187170, createdName=dzx0922896, createdTime=Mon Aug 31 05:01:00 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273329, encodeId=31d312e3329d4, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290164, encodeId=45c51290164b0, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294507, encodeId=d72b129450e7f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368743, encodeId=53511368e4314, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59228, encryptionId=3e3f592287a, topicName=日本厚生劳动省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438621, encodeId=8d7114386216d, content=<a href='/topic/show?id=9851500416c' target=_blank style='color:#2F92EE;'>#弥漫性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50041, encryptionId=9851500416c, topicName=弥漫性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527040, encodeId=e7ae152e040d2, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2020-09-21 snf701207

    #mAb#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1912252, encodeId=604219122527a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Sep 21 16:01:00 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702599, encodeId=0e991e02599ca, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Tue Jun 02 18:01:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634479, encodeId=ccd016344e94d, content=<a href='/topic/show?id=03454543528' target=_blank style='color:#2F92EE;'>#孤儿药认定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45435, encryptionId=03454543528, topicName=孤儿药认定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f66f22187170, createdName=dzx0922896, createdTime=Mon Aug 31 05:01:00 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273329, encodeId=31d312e3329d4, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290164, encodeId=45c51290164b0, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294507, encodeId=d72b129450e7f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368743, encodeId=53511368e4314, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59228, encryptionId=3e3f592287a, topicName=日本厚生劳动省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438621, encodeId=8d7114386216d, content=<a href='/topic/show?id=9851500416c' target=_blank style='color:#2F92EE;'>#弥漫性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50041, encryptionId=9851500416c, topicName=弥漫性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527040, encodeId=e7ae152e040d2, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2020-06-02 marlenexl

    #细胞淋巴瘤#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1912252, encodeId=604219122527a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Sep 21 16:01:00 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702599, encodeId=0e991e02599ca, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Tue Jun 02 18:01:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634479, encodeId=ccd016344e94d, content=<a href='/topic/show?id=03454543528' target=_blank style='color:#2F92EE;'>#孤儿药认定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45435, encryptionId=03454543528, topicName=孤儿药认定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f66f22187170, createdName=dzx0922896, createdTime=Mon Aug 31 05:01:00 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273329, encodeId=31d312e3329d4, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290164, encodeId=45c51290164b0, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294507, encodeId=d72b129450e7f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368743, encodeId=53511368e4314, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59228, encryptionId=3e3f592287a, topicName=日本厚生劳动省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438621, encodeId=8d7114386216d, content=<a href='/topic/show?id=9851500416c' target=_blank style='color:#2F92EE;'>#弥漫性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50041, encryptionId=9851500416c, topicName=弥漫性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527040, encodeId=e7ae152e040d2, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2020-08-31 dzx0922896

    #孤儿药认定#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1912252, encodeId=604219122527a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Sep 21 16:01:00 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702599, encodeId=0e991e02599ca, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Tue Jun 02 18:01:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634479, encodeId=ccd016344e94d, content=<a href='/topic/show?id=03454543528' target=_blank style='color:#2F92EE;'>#孤儿药认定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45435, encryptionId=03454543528, topicName=孤儿药认定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f66f22187170, createdName=dzx0922896, createdTime=Mon Aug 31 05:01:00 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273329, encodeId=31d312e3329d4, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290164, encodeId=45c51290164b0, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294507, encodeId=d72b129450e7f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368743, encodeId=53511368e4314, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59228, encryptionId=3e3f592287a, topicName=日本厚生劳动省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438621, encodeId=8d7114386216d, content=<a href='/topic/show?id=9851500416c' target=_blank style='color:#2F92EE;'>#弥漫性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50041, encryptionId=9851500416c, topicName=弥漫性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527040, encodeId=e7ae152e040d2, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-23 xiaoyeshuang

    #B细胞#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1912252, encodeId=604219122527a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Sep 21 16:01:00 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702599, encodeId=0e991e02599ca, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Tue Jun 02 18:01:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634479, encodeId=ccd016344e94d, content=<a href='/topic/show?id=03454543528' target=_blank style='color:#2F92EE;'>#孤儿药认定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45435, encryptionId=03454543528, topicName=孤儿药认定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f66f22187170, createdName=dzx0922896, createdTime=Mon Aug 31 05:01:00 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273329, encodeId=31d312e3329d4, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290164, encodeId=45c51290164b0, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294507, encodeId=d72b129450e7f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368743, encodeId=53511368e4314, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59228, encryptionId=3e3f592287a, topicName=日本厚生劳动省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438621, encodeId=8d7114386216d, content=<a href='/topic/show?id=9851500416c' target=_blank style='color:#2F92EE;'>#弥漫性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50041, encryptionId=9851500416c, topicName=弥漫性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527040, encodeId=e7ae152e040d2, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-23 bnjfy

    #弥漫性大B细胞淋巴瘤#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1912252, encodeId=604219122527a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Sep 21 16:01:00 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702599, encodeId=0e991e02599ca, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Tue Jun 02 18:01:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634479, encodeId=ccd016344e94d, content=<a href='/topic/show?id=03454543528' target=_blank style='color:#2F92EE;'>#孤儿药认定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45435, encryptionId=03454543528, topicName=孤儿药认定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f66f22187170, createdName=dzx0922896, createdTime=Mon Aug 31 05:01:00 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273329, encodeId=31d312e3329d4, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290164, encodeId=45c51290164b0, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294507, encodeId=d72b129450e7f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368743, encodeId=53511368e4314, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59228, encryptionId=3e3f592287a, topicName=日本厚生劳动省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438621, encodeId=8d7114386216d, content=<a href='/topic/show?id=9851500416c' target=_blank style='color:#2F92EE;'>#弥漫性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50041, encryptionId=9851500416c, topicName=弥漫性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527040, encodeId=e7ae152e040d2, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-23 chentianping

    #日本#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1912252, encodeId=604219122527a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Sep 21 16:01:00 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702599, encodeId=0e991e02599ca, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Tue Jun 02 18:01:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634479, encodeId=ccd016344e94d, content=<a href='/topic/show?id=03454543528' target=_blank style='color:#2F92EE;'>#孤儿药认定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45435, encryptionId=03454543528, topicName=孤儿药认定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f66f22187170, createdName=dzx0922896, createdTime=Mon Aug 31 05:01:00 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273329, encodeId=31d312e3329d4, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290164, encodeId=45c51290164b0, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294507, encodeId=d72b129450e7f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368743, encodeId=53511368e4314, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59228, encryptionId=3e3f592287a, topicName=日本厚生劳动省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438621, encodeId=8d7114386216d, content=<a href='/topic/show?id=9851500416c' target=_blank style='color:#2F92EE;'>#弥漫性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50041, encryptionId=9851500416c, topicName=弥漫性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527040, encodeId=e7ae152e040d2, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-23 839640778

    #日本厚生劳动省#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1912252, encodeId=604219122527a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Sep 21 16:01:00 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702599, encodeId=0e991e02599ca, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Tue Jun 02 18:01:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634479, encodeId=ccd016344e94d, content=<a href='/topic/show?id=03454543528' target=_blank style='color:#2F92EE;'>#孤儿药认定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45435, encryptionId=03454543528, topicName=孤儿药认定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f66f22187170, createdName=dzx0922896, createdTime=Mon Aug 31 05:01:00 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273329, encodeId=31d312e3329d4, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290164, encodeId=45c51290164b0, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294507, encodeId=d72b129450e7f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368743, encodeId=53511368e4314, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59228, encryptionId=3e3f592287a, topicName=日本厚生劳动省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438621, encodeId=8d7114386216d, content=<a href='/topic/show?id=9851500416c' target=_blank style='color:#2F92EE;'>#弥漫性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50041, encryptionId=9851500416c, topicName=弥漫性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527040, encodeId=e7ae152e040d2, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-23 zhouqu_8

    #弥漫性#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1912252, encodeId=604219122527a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Sep 21 16:01:00 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702599, encodeId=0e991e02599ca, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Tue Jun 02 18:01:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634479, encodeId=ccd016344e94d, content=<a href='/topic/show?id=03454543528' target=_blank style='color:#2F92EE;'>#孤儿药认定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45435, encryptionId=03454543528, topicName=孤儿药认定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f66f22187170, createdName=dzx0922896, createdTime=Mon Aug 31 05:01:00 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273329, encodeId=31d312e3329d4, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290164, encodeId=45c51290164b0, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50047, encryptionId=c5795004ece, topicName=弥漫性大B细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294507, encodeId=d72b129450e7f, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368743, encodeId=53511368e4314, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59228, encryptionId=3e3f592287a, topicName=日本厚生劳动省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438621, encodeId=8d7114386216d, content=<a href='/topic/show?id=9851500416c' target=_blank style='color:#2F92EE;'>#弥漫性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50041, encryptionId=9851500416c, topicName=弥漫性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527040, encodeId=e7ae152e040d2, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Sat Nov 23 00:01:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-23 jiangfeng5071

    #vedotin#

    0

相关资讯

拜耳旗下A型血友病药物Jivi在日本获批

拜耳制药近日宣布，日本厚生劳动省（MHLW）已批准Jivi®（BAY94-9027）用于日本12岁或以上成人和青少年A型血友病的治疗。